biote Corp. (NASDAQ:BTMD) Major Shareholder Purchases $22,615.46 in Stock

biote Corp. (NASDAQ:BTMD) major shareholder Guines Llc purchased 6,874 shares of the company’s stock in a transaction that occurred on Thursday, April 17th. The shares were acquired at an average price of $3.29 per share, for a total transaction of $22,615.46. Following the completion of the purchase, the insider now directly owns 4,164,300 shares in the company, valued at $13,700,547. This represents a 0.17 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Guines Llc also recently made the following trade(s):

• On Wednesday, April 9th, Guines Llc bought 13,532 shares of biote stock. The shares were acquired at an average cost of $3.21 per share, for a total transaction of $43,437.72.
• On Monday, April 7th, Guines Llc purchased 43,378 shares of biote stock. The stock was bought at an average cost of $3.15 per share, with a total value of $136,640.70.
• On Thursday, April 3rd, Guines Llc acquired 7,321 shares of biote stock. The shares were bought at an average price of $3.24 per share, for a total transaction of $23,720.04.
• On Monday, March 31st, Guines Llc bought 106,000 shares of biote stock. The stock was bought at an average price of $3.32 per share, with a total value of $351,920.00.
• On Monday, March 17th, Guines Llc purchased 100 shares of biote stock. The shares were bought at an average price of $3.74 per share, for a total transaction of $374.00.
• On Thursday, March 13th, Guines Llc acquired 750,000 shares of biote stock. The stock was purchased at an average price of $3.22 per share, with a total value of $2,415,000.00.

biote Stock Performance

Shares of BTMD stock opened at $3.30 on Monday. biote Corp. has a 52-week low of $3.04 and a 52-week high of $8.44. The business’s fifty day moving average is $3.92 and its 200 day moving average is $5.12. The company has a market capitalization of $180.54 million, a PE ratio of 12.69 and a beta of 1.17.

Analyst Ratings Changes

Separately, Craig Hallum lowered their target price on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th.

Institutional Trading of biote

Institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC raised its stake in biote by 52.3% in the third quarter. Barclays PLC now owns 77,196 shares of the company’s stock valued at $432,000 after purchasing an additional 26,510 shares in the last quarter. Sei Investments Co. raised its position in shares of biote by 56.4% during the 4th quarter. Sei Investments Co. now owns 18,321 shares of the company’s stock valued at $113,000 after buying an additional 6,605 shares in the last quarter. Kanen Wealth Management LLC purchased a new stake in shares of biote during the 4th quarter valued at $1,791,000. State Street Corp grew its position in biote by 13.7% in the third quarter. State Street Corp now owns 475,491 shares of the company’s stock worth $2,653,000 after acquiring an additional 57,290 shares in the last quarter. Finally, Jane Street Group LLC grew its position in biote by 24.7% in the third quarter. Jane Street Group LLC now owns 16,873 shares of the company’s stock worth $94,000 after acquiring an additional 3,342 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.